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ABSTRACT
Objectives: Applied and methodological evidence to the conduct of eco-
nomic evaluations alongside multinational clinical trials have appeared in
the literature over the last decade. Nevertheless, little is known about the
number and identity of countries participating in these studies. A struc-
tured review was carried out to assess the reporting of the multinational
nature of these studies.
Methods: A structured review was conducted by using online databases
from January 1996 to December 2007. Articles were included if they
reported cost-effectiveness analysis alongside a multinational randomized
trial with individual patient-level data on resource use and outcome in
more than one country. Key data extracted included country information,
sample size, unit cost collection, methods to calculate costs and effects,
and the reporting of incremental cost-effectiveness ratios.
Results: Sixty-ﬁve studies out of a total of 591 articles identiﬁed in the
original search fulﬁlled the inclusion criteria and were included in the
review. Information about countries participating in the trial was not
reported in 16 (26%) of the 65 studies. The overall sample size from all the
randomized controlled trials identiﬁed was estimated to be 172,401
patients. Country-speciﬁc sample size was reported for 74,852 (43%) of
the patients, but the country contribution was unknown for 97,549 (57%)
of the participants.
Conclusion: The reporting of the multinational nature of these studies
is currently inadequate. Therefore, future guidelines of transferability of
economic evaluations across settings should emphasize the importance of
reporting the number and identity of countries and their contribution to
the overall sample size in cost-effectiveness analyses alongside multina-
tional clinical trials.
Keywords: cost-effectiveness, economic evaluation, multinational rando-
mized controlled trials, multinational studies, review.
Introduction
Economic evaluation has become a valuable methodology to
inform health-care resource allocation in many developed and
developing countries [1,2]. As a result, there is an interest in
evaluating whether economic evidence obtained in one location
can meaningfully inform decision-makers in a different location
[3,4] (in this article, the terms location, jurisdiction, and setting
are used interchangeably). The extent to which such evidence can
be transferred to another setting is often referred to as the gen-
eralizability of the study, recently deﬁned by Sculpher et al. in an
extensive report on this issue as follows:
generalisability of economic evaluation is the extent to which
the results of a study based on a measurement in a particular
patient population and/or a speciﬁc context hold true for
another population and/or different context. [5]
Economic evaluations conducted alongside multinational clinical
trials are a special case because they include by deﬁnition data
from more than one patient population and one speciﬁc context.
As a result, the analyst is potentially able to use information from
that study to inform decision-makers in each of the countries that
contributed patients. Such evaluations may also have wider gen-
eralizability to other settings because of greater heterogeneity
represented in the patients participating. They are, therefore, a
potential mechanism to improve generalizability of studies.
Conducting randomized controlled trials on a multinational
basis is not a novel approach, and several authors have noted the
beneﬁts associated with these study designs [6,7]. Conducting
clinical trials across several countries may increase the recruit-
ment rate and the sample size available for analyses. Conse-
quently, the time needed to collect data, analyze, and present the
results of the clinical trial can be signiﬁcantly reduced. In addi-
tion, the clinical and research expertise and knowledge from
experienced trial centers in a particular country can be trans-
ferred to centers with less experience in other countries. The
pharmaceutical industry has found additional important advan-
tages in running their studies across different countries [8–10].
For example, detailed information on unit costs, resource use,
and effects can be collected across several jurisdictions, providing
valuable data relevant to pricing, marketing, strategic planning,
and reimbursement decisions in different markets.
Surveys of multinational economic evaluations have been
published in recent years. Barbieri et al., for instance, identiﬁed
46 multinational economic evaluations of pharmaceuticals in
Europe from 1998 to 2001 and suggested that variability of
cost-effectiveness estimates across countries was inﬂuenced
mainly by resource use differences and the real value of cost-
effectiveness thresholds across jurisdictions [11]. Halliday and
Darba explored how cost data were reported in 54 multinational
economic evaluations for a period of 10 years up to 2002 and
found wide variability in the quality of the reporting of these
studies [12]. Both surveys included trial-based studies and eco-
nomic models in their reviews.
Torti et al. identiﬁed 23 studies in a literature search from
1995 to 2004 of multinational economic evaluations alongside
clinical trials in cardiology and extracted the categories of
resources included, the costing strategies adopted, and extrapo-
lation methods beyond the clinical trial period in these studies
[13]. The authors concluded that more guidance is needed
because design and analysis methods differed widely across
studies.
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The review of generalizability by Sculpher et al. included a
systematic review of economic evaluations undertaken alongside
multicenter randomized controlled trials from 1994 to 2000 [5].
Multinational economic evaluations alongside clinical trials are
by deﬁnition multicenter studies, and, hence, 21 studies of this
type were retrieved in their review, which concentrated on iden-
tifying the type of cost analysis performed. They found that
around 50% of the studies applied a single set of unit costs to
resource use in all countries.
All these reviews have extracted important information to
understand cost-effectiveness analysis alongside multinational
clinical trials. Nevertheless, little is known about the multina-
tional characteristics of such studies. For instance, information
on the number of participating countries that contributed data
and on their contribution to the overall sample size of the study
have not yet been estimated. In addition, detailed data on the
collection of unit costs and the type of analyses conducted across
countries have been only partially reported [5,12,13]. Therefore,
this article explores the multinational nature of multinational
cost-effectiveness analyses using a structured review of published
studies from 1996 to 2007.
Methods
The Structured Review
Articles were included if they reported cost-effectiveness analyses
alongside a multinational randomized controlled trial with indi-
vidual patient-level data on resource use and health outcomes in
more than one country. For other relevant articles to be identiﬁed,
articles were also included if analytical strategies either for
resource use, health outcomes, or both that could assist in the
performance of cost-effectiveness analysis alongsidemultinational
clinical trials were explored. For the reporting of the review to be
facilitated, the identiﬁed evidence was categorized in two groups:
empirical or applied evidence, and methodological studies.
These inclusion criteria ensured retrieval of, for example, the
main cost-effectiveness results from a trial and a second publica-
tion using the same trial data to explore a methodological ques-
tion such as different methods of analyzing cost-effectiveness
analysis alongside multinational clinical trials. In this case, the
former article would be categorized as empirical, whereas the
latter would be categorized as methodological. Recent articles
have provided good overviews on the methodology surrounding
the analysis and presentation of results from multinational cost-
effectiveness analysis [14,15]. Consequently, this article concen-
trates in reviewing and extracting those publications categorized
as empirical or applied only.
Cost-effectiveness analyses alongside nonrandomized multi-
national clinical trials, economic models, published abstracts
of conference proceedings, research protocols, discrete choice
experiments, and willingness to pay studies were not included in
the review.
The core search strategy was performed in MEDLINE,
EMBASE and the National Health Service economic evaluation
database. Cross-reference searching of eligible articles was also
carried out.
Different spellings and combinations of the following terms
were used in the search strategy: multinational, clinical, trial,
randomized, multicountry, cost, cost-effectiveness, cost-utility,
cost-beneﬁt. The use of terms that potentially could retrieve a
large list of unsuccessful results, such as “country/ies” or
“multicenter/center” was avoided (some authors use the term
“multicenter/center” to refer to multinational studies, and omit-
ting this term in the search strategy could have left potential
evidence unidentiﬁed. Nevertheless, it was expected that cross-
references would help to identify these articles and minimize any
potential bias).
Articles published from January 1996 to December 2007
were included in this review.
The title and abstract of all articles identiﬁed were reviewed,
and if they fulﬁlled the inclusion criteria, a complete printed
documentwas electronically downloaded or ordered. For ambigu-
ous results, a full document was also retrieved and examined.
A keyword pro forma was developed for the extraction of
data. The main information extracted included
1. the overall sample size of the trial;
2. the number of participating countries and their correspond-
ing contribution to the sample size;
3. the categories of resource use collected;
4. the sources for unit costs, the country of origin, and adjust-
ments for missing unit cost information;
5. the sources and methods to calculate costs;
6. the currency adjustment adopted;
7. the sources and methods used in the effectiveness analysis;
and
8. the reporting of the incremental cost-effectiveness results
(ICERs).
The World Bank income classiﬁcation that divides countries
according to 2007 gross national income (GNI) per capita was
used in the RESULTS section: low income, $935 or less; middle
income, $936 to $11,455; and high income, $11,456 or more.
For trends across the study period of the review to be estimated,
estimates were also calculated and presented from the periods
from 1996 to 2000 and from 2001 to 2007.
All analyses were carried out in Excel 2007 and STATA 10
[16]. Descriptive statistics and standard statistical tests were used
to report the results of this review.
Classiﬁcation of the Analytical Approach of Studies
The terminology proposed by Reed et al. to describe the analytical
approach used in multinational economic evaluations alongside
trials is adopted in this review to categorize the studies [17].
Studies are classiﬁed ﬁrst depending onwhether patients in a single
country (or a subset of countries) or patients in all countries
contributed to the sample size for the effectiveness and resource
use data used in the analysis. A fully pooled analysis is based on
effectiveness and resource use data from patients in all countries.
A partially split analysis is based on estimates of effectiveness data
from all countries, but resource use data are based on a single
country (or a subset of countries). In a fully split analysis, esti-
mates of effectiveness and resource use are based on the same
group of patients in a single country (or a subset of countries).
Studies are then further classiﬁed, depending on the costing
method performed. If unit cost estimates from each particular
country are applied to the resources used in those countries, it is
described as a multicountry costing. In a one-country costing, a
unit cost estimate from one country is applied to resource use in all
countries, a subgroup of countries, or a single country.
Results
Descriptive Information of the Overall Review
A schematic diagram of the overall identiﬁcation and review
process is presented in Figure 1. A total of 591 articles were
identiﬁed from the original search strategy. From those, 441
articles were excluded because they clearly did not fulﬁll the
inclusion criteria. The majority of these articles were economic
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evaluation models, cost-analyses using data from randomized
and nonrandomized designs, and nonrelated research. Full
printed copies were obtained from 150 potentially relevant
articles. After careful evaluation, 79 articles were excluded from
the review, leaving 71 articles fulﬁlling the inclusion criteria.
Cross-reference checks from the identiﬁed studies yielded
another 14 relevant articles. The ﬁnal sample of this review
comprises 65 studies after methodological exercises were
excluded. A list of the references of this ﬁnal sample is presented
and can be found at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i1_Rivero-Arias.asp.
The frequency of studies published annually since 1996 is
presented in Figure 2. The chart shows no clear trend in the
frequency of multinational economic evaluation publications.
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Figure 1 Schematic diagram of overall identiﬁcation and review process. †Research consensus, international comparisons, and general review. ‡Willingness to pay
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Figure 2 Frequency of multinational economic
evaluations published from 1996 to 2007.
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The Multinational Nature of the Studies
Detailed information on the number of participating countries
and their contribution to the overall sample size was reported in
20 (31%) of the 65 studies. A total of 29 (45%) of the 65
publications provided limited information about their interna-
tional dimension, for example, articles that mentioned the
number of participating countries but provided no information
on which countries were included or the contributing sample size
from each country. Finally, 16 (25%) of the 65 studies did not
report any information on the multinational nature of the study.
A detailed examination of countries contributing data and of
the number of studies to which data were contributed is presented
in Table 1. The overall sample size from all the randomized
controlled trials identiﬁed was estimated to be 172,401 patients.
Country-speciﬁc sample sizewas reported for 74,852 (43%) of the
patients, but the country contribution was unknown for 97,549
(57%) of the participants. A total of 53,852 (72%) of the patients
in studies reporting country-speciﬁc sample size came from high-
income countries, and 11,070 (15%) from middle-income coun-
tries. The majority of middle-income countries participating in
these studies did so during 2004 and 2005. Centers from the
United Kingdom participated in 23 of the studies, making the UK
the country with the most frequent involvement in research of this
type. Nevertheless, the United States recruited the largest number
of patients across all countries identiﬁed in the review.
Table 2 provides estimates on the multinational nature of the
studies included in the review. A total of 31 (48%) of the 65
studies were conducted entirely in high-income countries and
contributed 63,693 (37%) patients to the overall reported
sample size across all studies. The mean (range) number of coun-
tries per study was estimated to be 7 (2–33) across all studies and
5.5 (2–15) across studies in high-income countries, a nonsigniﬁ-
cant difference (P = 0.1794). The mean (range) sample size per
study was estimated to be 2655 (44–14,703) across all studies
and 2055 (44–10,305) across studies in high-income countries, a
nonsigniﬁcant difference (P = 0.4039).
Table 2 also shows the mean (range) proportion of patients
from the largest contributing country by study period. Nonsig-
niﬁcant differences were found between groups and across time
period (1996–2000: P = 0.900; 2001–2007: P = 0.5726). The
largest contributing country recruited, on average, around 38%
of all the patients participating in the study.
Table 3 shows the unit cost collection approach used in the
studies. A total of 39 (62%) of the 63 studies collected unit costs
data from one country and had an associated mean (range) of 5.6
(2–16) countries per study. Studies collecting unit cost informa-
tion from two to four countries had a mean (range) of 5.4 (2–12)
countries per study. Thirteen (21%) studies collected unit cost
data from more than four countries, and 11.9 countries partici-
pated in these studies on average. An analysis of variance con-
ﬁrmed a signiﬁcant difference in the mean number of countries
per study among groups (F = 6.08, P < 0.01). No differences in
the collection of unit costs were found across time.
Table 4 reports the type of unit costs data collected within
each country. The majority of studies collected national average
unit costs or used mixed sources to perform the cost analysis. It
seems that there has been a move from using mixed sources
toward national average unit costs after 2000, but no statistical
difference between periods was detected to validate this result
(c2 = 8.59, P = 0.072).
The Collection of Effectiveness Data
A total of 58 (89%) of the 65 studies used trial-wide health
outcome data to conduct their effectiveness analysis, indicating
Table 1 Description of countries contributing data and number of
studies to which data were contributed by using theWorld Bank classiﬁ-
cation category
Country
Number of
patients
reported
Percentage (%)
contribution
from overall
sample size
Number of
studies
High-income countries
US 19,926 11.56 18
Canada 5,042 2.92 14
Sweden 5,029 2.92 16
UK 3,266 1.89 23
Italy 2,639 1.53 11
Norway 2,518 1.46 11
The Netherlands 2,284 1.32 11
Denmark 2,278 1.32 14
Finland 2,069 1.20 11
Germany 1,989 1.15 17
France 1,281 0.74 21
Greece 966 0.56 3
Spain 925 0.54 18
Australia 744 0.43 9
Hungary 584 0.34 4
Belgium 466 0.27 11
Czech Republic 379 0.22 3
Iceland 314 0.18 3
Austria 218 0.13 6
Luxembourg 185 0.11 1
Slovak Republic 184 0.11 1
Switzerland 174 0.10 5
New Zealand 144 0.08 2
Israel 85 0.05 3
Portugal 72 0.04 3
Singapore 46 0.03 1
Ireland 38 0.02 2
United Arab Emirates 7 0.00 1
Total high income 53,852 31.22
Middle-income countries
Russia 3,146 1.82 3
South Africa 2,980 1.73 7
Argentina 2,291 1.33 5
India 718 0.42 1
Colombia 474 0.27 1
Brazil 401 0.23 4
Poland 348 0.20 2
Cuba 254 0.15 1
Albania 108 0.06 1
Egypt,Arab Rep. 108 0.06 1
Mexico 67 0.04 3
Turkey 46 0.03 1
Venezuela, RB 33 0.02 1
Malaysia 32 0.02 1
Jordan 28 0.02 1
Thailand 20 0.01 1
Sri Lanka 8 0.00 1
Chile 4 0.00 2
Peru 2 0.00 1
Uruguay 2 0.00 1
Total middle income 11,070 6.41
Low-income countries
Zimbabwe 611 0.35 1
Uganda 584 0.34 1
Nigeria 466 0.27 1
Pakistan 297 0.17 1
Bangladesh 196 0.11 1
Malawi 109 0.06 1
Yemen Rep. 109 0.06 1
Ghana 106 0.06 1
Sierra Leone 34 0.02 1
Total low income 2,512 1.44
Other(s)* 7,418 4.30
Total country sample size
reported
74,852 43.42
Unknown country contribution 97,549 56.58
Total sample size from all
randomized controlled trials
172,401
*Some articles reported sample size by regions but did not clarify the participating countries
(e.g., Europe, South America,Western Europe, North America).
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the dominance of fully pooled and partially split methods in this
type of study (Table 5). Although no differences were found in
the analysis and reporting of effectiveness data across periods,
the number of studies using health-related quality of life data
seems to have increased over the years. Quality adjusted life-
years (QALYs) were used as the main outcome measure in nine
studies, with the EuroQol ﬁve-dimension generic instrument
(EQ-5D) UK tariff, the EQ-5D thermometer, and mapping algo-
rithms being the main approaches used to calculate utility values.
The Reporting of Cost-Effectiveness Analysis
Fully pooled, one-country costing with 66% (43 of the 65
articles) and fully pooled, multicountry costing with 15% (10
of the 65 publications) were the preferred methodological
approaches adopted to analyze and report the results from these
studies (Table 6). Fully and partially split were less common,
being used in studies where the proportion of patients from the
largest contributing country was greater than 45% on average.
Although no signiﬁcance differences between periods were
detected (c2 = 7.31, P = 0.121), a description of the methodologi-
cal approaches by year of publication is presented in Figure 3.
Table 7 shows that country-speciﬁc ICERs were reported in
10 (15%) of the 65 studies and that one estimate of ICER for all
countries was reported in 25 (38%) of the 65 studies. ICERs
were not reported in 24 (37%) of the 65 articles, but this was
particularly a characteristic in studies published before the year
2000 [16 (53%) of the 30 studies] with the reporting improving
signiﬁcantly after then, with only 8 (23%) of the 35 studies not
combining costs and effects. A similar pattern was observed in
the studies when handling uncertainty for the ICERs. Table 8
suggests a signiﬁcant improvement when reporting measures of
uncertainty for ICERs after the year 2000.
Detailed results of the cost-effectiveness analyses performed
in multicountry studies and studies reporting country-speciﬁc
ICERs are presented and can be found at: http://www.ispor.org/
Publications /value /ViHsupplementary /ViH13i1_Rivero -Arias .
asp.
Funding of Studies
A total of 53 (82%) of the 65 studies identiﬁed in this review
were funded by the pharmaceutical industry; 5 (7%) of the 65
were funded by nonindustry organizations, and the remainder 7
(11%) of the 65 did not speciﬁed the funding received. The
studies funded by the pharmaceutical industry comprise 135,521
(79%) of the overall sample size from all the randomized con-
trolled trials and were conducted exclusively in high-income
countries in 24 (62%) of the 39 studies.
Discussion
Using a structured review, this review identiﬁed 65 cost-
effectiveness analyses alongside multinational clinical trials from
1996 to 2007 and extracted relevant information on the multi-
national nature of these studies. Around 57% of the overall
sample failed to describe the contribution of the countries par-
ticipating in the trial, indicating poor reporting of the multina-
Table 2 Descriptive statistics of the multinational nature of the studies included in this review
n All studies n
Studies conducted entirely
in high-income countries
Total number of studies 65 31
Total number of participating countries 57 28
Total sample size across studies 172,401 63,693
Mean (range) number of countries per study 48 7 (2–33) 30 5.5 (2–15)
Mean (range) sample size per study 65 2,655 (44–14,703) 31 2,055 (44–10,305)
Mean (range) sample size per country 199 376 (1–3,964) 57 448 (1–3,522)
Mean (range) proportion of patients
from the largest contributing country*
Overall
1996–2000 8 0.37 (0.20–0.60) 6 0.36 (0.20–0.60)
2001–2007 12 0.37 (0.11–0.75) 5 0.43 (0.11–0.75)
*These parameters could only be calculated by using studies that reported detailed information on the countries participating and contributing sample size.
Table 3 Unit costs information used in the costing analysis in the
studies included in the review
Collection of unit cost information
Number (%)
of studies*
Mean (range) number of
countries in the study
Overall
Unit cost from one country only 39 (62) 5.6 (2–16)†
Unit cost from 2–4 countries 11 (17) 5.4 (2–12)†
Unit cost from 5+ countries 13 (21) 11.9 (5–33)†
1996–2000
Unit cost from one country only 19 (66) 5.1 (2–15)
Unit cost from 2–4 countries 5 (17) 3.6 (2–6)
Unit cost from 5+ countries 5 (17) 7.4 (5–15)
2001–2007
Unit cost from one country only 20 (59) 5.9 (2–16)‡
Unit cost from 2–4 countries 6 (18) 6.8 (4–12)‡
Unit cost from 5+ countries 8 (24) 14.8 (6–33)‡
*Two countries did not provide detailed data in the collection of unit costs across countries.
†F = 6.08, P < 0.01.
‡F = 5.15, P = 0.01.
Table 4 Unit cost collection approach used in the studies included in the review
Single
center (%)
Multiple center
unit costs (%)
National average
unit costs (%)
Mixed
sources (%)
Not
clear (%)
Number
of studies
Overall 3 (5) 3 (5) 35 (54) 21 (32) 3 (5) 65
1996–2000 2 (7) 2 (7) 11 (37) 12 (40) 3 (10) 30
2001–2007 1 (3) 1 (3) 24 (69) 9 (26) 0 (0) 35
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tional dimension. In addition, approximately 20% of the articles
did not recognize the multinational nature of the study in any
section of the article.
In most studies, one country contributed a large proportion
of the overall sample size. This was clearly inﬂuential when
deciding on the method to analyze cost-effectiveness data. Studies
where the largest country contributed less than 36% of the total
sample size preferred a fully pooled costs and effects approach to
conduct their analyses. Nevertheless, studies where one country
contributed 45% or more of the total generally split the data
instead of pool them across all countries.
The selection of countries in the studies was conducted ad hoc
rather than at the design stage. The implications of this selection
are still under evaluation, but a number of methods have already
been suggested to deal with this issue. Current statistical methods
to analyze costs and outcomes data across settings suggest the
use of multilevel models to estimate cost-effectiveness [15].
Multilevel models require a large number of units in the level
indicating the cluster, that is, number of countries, to ensure
variability between levels. On average, seven countries per study
Table 5 Health outcome data collected and type of effectiveness analy-
sis conducted in the studies
Summary of effectiveness analysis
Overall
(%)
1996–2000
(%)
2001–2007
(%)
Handling of the effectiveness data
Trial-wide effectiveness data used 58 (89) 26 (87) 32 (91)
Subsample of cases used 7 (11) 4 (13) 3 (9)
Health outcomes used in the analysis
Disease-speciﬁc 28 (43) 16 (53) 12 (34)
Life-years 23 (35) 11 (37) 12 (34)
HRQoL
EQ-5D 9 (14) 1 (3) 8 (23)
SF-36 2 (3) 1 (3) 1 (3)
Other 3 (5) 1 (3) 2 (6)
Utility calculation in studies presenting
quality-adjusted life-year (QALYs)
EQ-5D UK tariff 4 (44) — 4 (57)
EQ-5D thermometer 2 (22) 1 (50) 1 (14)
Utility mapping 3 (33) 1 (50) 2 (29)
EQ-5D, Euroqol ﬁve-dimension generic instrument; HRQoL, health-related quality of life;
QALYs, quality-adjusted life-years; SF-36, short-form 36 items generic instrument.
Table 6 Ways in which cost-effectiveness data were analyzed in the studies by using Reed et al. [17] classiﬁcation
Classiﬁcation
Overall
Freq (%)
1996–2000
Freq (%)
2001–2007
Freq (%)
Detailed information
studies (n)
Mean (range) proportion of patients
from the largest contributing country*
Fully pooled, one-country costing 43 (66) 19 (63) 24 (69) 9 0.32 (0.11–0.44)
Fully pooled, multicountry costing 10 (15) 2 (7) 8 (23) 6 0.36 (0.20–0.54)
Fully split, one-country costing 6 (9) 4 (13) 2 (6) 3 0.46 (0.24–0.75)
Partially split, one-country costing 5 (8) 4 (13) 1 (3) 2 0.49 (0.40–0.60)
Partially split, multicountry costing† 1 (2) 1 (3) 0 —
Total 65 30 35
*These parameters could only be calculated by using studies that reported detailed information on the countries participating and contributing sample size.
†This classiﬁcation is possible if health outcomes have been analyzed by using data from all countries, but costs have been analyzed by using a subset of countries.
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Figure 3 Description of methodological ap-
proaches used in the studies by year of publication.
Table 7 Presentation of country-speciﬁc ICER results in the applied
studies
Classiﬁcation
Overall
(%)
1996–2000*
(%)
2001–2007*
(%)
One estimate of ICER was
reported for all countries
25 (38) 8 (27) 17 (49)
Not reported 24 (37) 16 (53) 8 (23)
Country-speciﬁc ICERs were
reported for each country†
10 (15) 2 (7) 8 (23)
One estimate of ICER for
a particular country
6 (9) 4 (13) 2 (6)
Total 65 30 35
*Statistical signiﬁcant difference between periods c2 = 9.85, P = 0.020.
†The study by Simon et al. [18] divides group of patients by GNI and does not report ICERs
by country but GNI regions.
GNI, gross national income; ICER, incremental cost-effectiveness ratio.
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contributed to the data collection in the trials. Therefore, it is
likely that the use of this method in the majority of studies
identiﬁed in this review would have been very limited [15].
A total of 31 of the 65 studies identiﬁed were conducted
exclusively in high-income countries, and the remainder also
recruited heavily from high-income countries. A weak trend of
countries from middle-income countries participating in these
studies was identiﬁed during the years 2004 and 2005. Never-
theless, this trend disappears after that period. All the low-
income countries identiﬁed in this review participated in just one
of the studies [18]: the study by Simon et al. comparing the use of
magnesium sulfate for the treatment of pre-eclampsia. This low
participation rate from low-income countries perhaps explains
why disability-adjusted life-years were not used as the primary
outcome measure in any of the studies.
This review attempted to identify whether the reporting of
the multinational nature of these studies had improved over
the years. Although some trends were observed between time
periods, few signiﬁcant differences were detected probably
because of the small sample size of 65 studies in the review.
Nevertheless, the signiﬁcant improvement in the reporting of
ICERs and handling of uncertainty after 2000 suggests that
guidelines on the conduct of economic evaluation of health-care
technologies have had some effect.
Several discussions on generalizability and transferability of
economic evaluations across geographic locations have recently
been published [5,15,19–21]. The ISPOR Good Research Prac-
tices Task Force Report, for example, reviewed what current
national guidelines in economic evaluation state about transfer-
ability [15]. The report suggested that most guidelines did
mention transferability and the potential of using information
from a different jurisdiction to inform their own setting, but
recommendations on how to use external information varied
across national guidelines. The Task Force Report emphasized
the use of multilocation clinical trial data to adjust cost-
effectiveness information for a particular setting. It was suggested
that descriptive statistics and tests for heterogeneity should be
explored ﬁrst to identify any potential differences across jurisdic-
tions. Then, more sophisticated statistical modeling should be
implemented to adjust cost-effectiveness estimates in a particular
location. The use of these methods should be guided by the
following criteria: “1) number of jurisdictions (e.g., countries,
centers); 2) exchangeability or nonexchangeability of data; and
3) the availability of covariates (e.g., center and country level)”
[15]. Nevertheless, the present review suggests that quite basic
information such as the number and identity of countries par-
ticipating is currently reported inadequately. Therefore, decision-
makers will ﬁnd it difﬁcult to decide whether a particular study is
of interest to their own setting.
Individual patient-level data from multinational clinical trials
are likely to inform parameters in model-based studies, which
aim to inform cost-effectiveness in a particular country. This type
of study was not included in the current review, and, currently,
little is known about the quality of these studies. Future reviews
should extract relevant information that helps ﬁll the current gap
in the literature on this issue.
Only one assessor evaluated the evidence included in the ﬁnal
sample of this review, and, although the search was performed in
a transparent and structured manner, the ﬁnal sample included in
the review cannot be considered exhaustive. Nevertheless, the
large number of references extracted compared with other
reviews suggests that, if any relevant evidence was left unidenti-
ﬁed, it is unlikely to cause bias in the results.
The results from this review suggest that future guidelines on
transferability of economic evaluations across settings should
emphasize the importance of reporting the number and identity
of countries and their contribution to the overall sample size in
cost-effectiveness analyses alongside multinational clinical trials.
Both analysts and decision-makers will beneﬁt from this
improvement. From the analyst’s side, reporting participating
countries and contributing sample size will improve the overall
quality of the study. Decision-makers will also greatly beneﬁt
from this improvement because they will be better informed on
the relevance of the study to their particular setting.
Source of ﬁnancial support: Oliver Rivero-Arias is funded by a Doctoral
Research Fellowship from the National Institute of Health Research. The
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